Report / Paper metadata
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.
A forty-one-patient Chinese cohort from MonumenTAL-1 described oral, skin and nail adverse events during talquetamab treatment. The paper focuses on one group of adverse events; it should not be read as a complete safety profile or proof that all treatment risks are mild.
Who was studied?
The report concerned adults with heavily pretreated relapsed or refractory multiple myeloma in a Chinese cohort of the phase I/II MonumenTAL-1 study. Twenty-nine patients were in a weekly treatment cohort and twelve in a treatment-every-two-weeks cohort. Their treatment exposure and follow-up differed, so these groups are not interchangeable.
Which adverse events were described?
The report focuses on events associated with the GPRC5D target in tissues beyond the tumour. Commonly reported categories were taste changes and dry mouth, skin effects and nail disorders. Most were grade one or two; the abstract also reports one grade-three non-rash skin event in the weekly cohort.
What happened during follow-up?
The authors report that between 50% and 100% of these events had resolved by the data cutoff, depending on the event category. That range does not mean every patient had recovered from every adverse event. Supportive therapies were used, and one case of grade-two weight decrease required a dose change.
What is outside the scope?
This small descriptive cohort does not cover every possible talquetamab complication or establish the absence of rare harms. Nor does it compare the two schedules as a randomised safety trial. The abstract's focus on oral, skin and nail effects cannot justify a general statement that the medicine is safe. Treatment choices and adverse-event management require the full clinical context and current product information.
- Journal
- Hematology (Amsterdam, Netherlands)
- Kind
- Paper metadata
- Identifier
- PMID 42679119